Cargando…
Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells
Arsenic trioxide (ATO) has been used for the treatment of acute promyelocytic leukemia (APL). Although ATO modulates cell cycle progression and apoptosis in APL cells, its exact mechanism of action remains elusive. In this research, we investigated its effects on E2F1, cyclin E, p53, pRb, and PI3K s...
Autores principales: | Kumar, Sanjay, Tchounwou, Paul B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453914/ https://www.ncbi.nlm.nih.gov/pubmed/34042274 http://dx.doi.org/10.1002/tox.23299 |
Ejemplares similares
-
Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia
por: Yedjou, Clement, et al.
Publicado: (2009) -
Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells
por: Kumar, Sanjay, et al.
Publicado: (2014) -
Dose- and Time-Dependent Response of Human Leukemia (HL-60) Cells to Arsenic Trioxide Treatment
por: Yedjou, Clement G., et al.
Publicado: (2006) -
Basic Mechanisms of Arsenic Trioxide (ATO)-Induced Apoptosis in Human Leukemia (HL-60) Cells
por: Yedjou, Clement, et al.
Publicado: (2010) -
Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells
por: Rogers, Christian S, et al.
Publicado: (2014)